During progression of melanoma, malignant melanocytes can be reprogrammed into
mesenchymal-like cells through a process similar to epithelial-mesenchymal transition (EMT), …

Disruption of the endothelial barrier by tumour-derived secreted factors is a critical step in
cancer cell extravasation and metastasis. Here, by comparative proteomic analysis of …

Resistance to BRAF/MEK inhibitor therapy in BRAF V600 ‐mutated advanced melanoma
remains a major obstacle that limits patient benefit. Microenvironment components including …

These findings reveal a biomechanical adaptation of melanoma cells to oncogenic BRAF
pathway inhibition, which fuels a YAP/MRTF-dependent feed-forward loop associated with …

Hypoxia is a major feature of the solid tumor microenvironment and is known to be associated
with tumor progression and poor clinical outcome. Recently, we reported that hypoxia …

Advanced cutaneous melanoma is one of the most challenging cancers to treat because of
its high plasticity, metastatic potential, and resistance to treatment. New targeted therapies …

Rationale: Alternative therapeutic strategies based on tumor-specific molecular targets are
urgently needed for triple-negative breast cancer (TNBC). The protease cathepsin D (cath-D) …

Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of patients
diagnosed with acute myeloid leukemia (AML). Despite its efficiency against AML cells, …

Communication between dedifferentiated melanoma cells and lymph node fibroblasts
reprograms the biomechanical properties of the premetastatic lymph node niche to promote tumor …

Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype and
lacks specific targeted therapeutic agents. The current mechanistic evidence from cell‐based …